Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a se...

Full description

Bibliographic Details
Main Authors: Babbs, A, Berg, A, Chatzopoulou, M, Davies, K, Davies, S, Edwards, B, Elsey, D, Emer, E, Figuccia, A, Fletcher, A, Guiraud, S, Harriman, S, Moir, L, Robinson, N, Rowley, J, Russell, A, Squire, S, Thomson, J, Tinsley, J, Wilson, F, Wynne, G
Format: Journal article
Language:English
Published: Elsevier 2019
Description
Summary:Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a second generation utrophin modulator preclinical candidate, and an asymmetric synthesis of its constituent enantiomers. The pharmacological properties of both enantiomers were evaluated in vitro and in vivo. No significant difference in the activity or efficacy was observed between the two enantiomers; activity was found to be comparable to the racemic mixture.

Similar Items